MA52077A - Inhibiteurs de canal à potentiel de récepteur transitoire à base d'oxadiazole - Google Patents

Inhibiteurs de canal à potentiel de récepteur transitoire à base d'oxadiazole

Info

Publication number
MA52077A
MA52077A MA052077A MA52077A MA52077A MA 52077 A MA52077 A MA 52077A MA 052077 A MA052077 A MA 052077A MA 52077 A MA52077 A MA 52077A MA 52077 A MA52077 A MA 52077A
Authority
MA
Morocco
Prior art keywords
oxadiazole
channel inhibitors
potential channel
based transient
receiver potential
Prior art date
Application number
MA052077A
Other languages
English (en)
Inventor
Francis Beaumier
Huifen Chen
Lea Constantineau-Forget
Martin Déry
Chantal Grand-Maître
Robin Larouche-Gauthier
Luce Lépissier
Claudio Sturino
Jack Alexander Terrett
Elisia Villemure
Matthew Volgraf
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA52077A publication Critical patent/MA52077A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Ink Jet (AREA)
  • Pyrrole Compounds (AREA)
  • Metal-Oxide And Bipolar Metal-Oxide Semiconductor Integrated Circuits (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
MA052077A 2018-03-19 2019-03-18 Inhibiteurs de canal à potentiel de récepteur transitoire à base d'oxadiazole MA52077A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862644987P 2018-03-19 2018-03-19
US201862676057P 2018-05-24 2018-05-24
US201862725488P 2018-08-31 2018-08-31
US201962812806P 2019-03-01 2019-03-01

Publications (1)

Publication Number Publication Date
MA52077A true MA52077A (fr) 2021-01-27

Family

ID=65952221

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052077A MA52077A (fr) 2018-03-19 2019-03-18 Inhibiteurs de canal à potentiel de récepteur transitoire à base d'oxadiazole

Country Status (21)

Country Link
US (4) US10710994B2 (fr)
EP (1) EP3768260B1 (fr)
JP (2) JP7095106B2 (fr)
KR (2) KR102533094B1 (fr)
CN (1) CN111867585A (fr)
AU (1) AU2019237992B2 (fr)
CA (1) CA3091486A1 (fr)
CL (1) CL2020002399A1 (fr)
CO (1) CO2020011852A2 (fr)
CR (1) CR20200413A (fr)
ES (1) ES3052569T3 (fr)
IL (2) IL276654B2 (fr)
MA (1) MA52077A (fr)
MX (1) MX2020009657A (fr)
MY (1) MY209839A (fr)
PE (1) PE20210660A1 (fr)
PH (1) PH12020551501A1 (fr)
SG (1) SG11202009136RA (fr)
TW (2) TWI829676B (fr)
UA (1) UA128787C2 (fr)
WO (1) WO2019182925A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202006296YA (en) 2018-01-19 2020-08-28 Cytokinetics Inc Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
US10710994B2 (en) * 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
EP3814343B1 (fr) 2018-06-26 2023-01-11 Cytokinetics, Inc. Inhibiteurs de sarcomères cardiaques
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
US10981905B2 (en) 2018-08-31 2021-04-20 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents
JP7688339B2 (ja) * 2020-01-22 2025-06-04 国立研究開発法人理化学研究所 新規化合物、およびその利用
WO2021233752A1 (fr) 2020-05-19 2021-11-25 Bayer Aktiengesellschaft Antagonistes de trpa1 pour le traitement de maladies associées à la douleur et à l'inflammation
FR3114235A1 (fr) 2020-09-18 2022-03-25 Université Grenoble Alpes Inhibition du canal trpa1 astrocytaire comme nouvelle cible therapeutique neuroprotectrice dans les phases prodromales de la maladie d’alzheimer
KR20240015622A (ko) 2021-03-04 2024-02-05 싸이토키네틱스, 인코포레이티드 심장 근절 억제제
CA3211048A1 (fr) * 2021-04-14 2022-10-20 Boehringer Ingelheim International Gmbh Derives de 3h,4h,5h,6h,7h-pyrimido[4,5-b][1,4]oxazine-4,6-dione en tant qu'inhibiteurs de trpa1
US11878981B2 (en) * 2021-04-14 2024-01-23 Boehringer Ingelheim International Gmbh Substituted 1,2,4-oxadiazoles as TRPA1 inhibitors
IT202100015098A1 (it) 2021-06-09 2022-12-09 Flonext S R L Composto antagonista del canale trpa1 per uso in patologie degenerative della retina
CN118765275A (zh) 2022-02-28 2024-10-11 基因泰克公司 用于制备苯基四氢呋喃化合物的方法
CN118206482B (zh) * 2024-03-05 2025-04-25 山东京博生物科技有限公司 一种4-三氟甲基烟酰胺的合成方法
WO2026109049A1 (fr) * 2024-11-25 2026-05-28 武汉朗来科技发展有限公司 Composé utilisé en tant qu'inhibiteur de trpa1, composition pharmaceutique et utilisation associées
WO2026139068A1 (fr) * 2024-12-26 2026-07-02 武汉朗来科技发展有限公司 Composé utilisé en tant qu'inhibiteur de trpa1, composition pharmaceutique associée et utilisation associée

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0102324A3 (fr) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipides et composés tensio-actifs en phase aqueuse
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
IL96891A0 (en) 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
AU677216B2 (en) 1992-07-27 1997-04-17 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Targeting of liposomes to the blood-brain barrier
KR100542780B1 (ko) * 2000-04-21 2006-01-11 시오노기세이야쿠가부시키가이샤 항암 효과를 갖는 옥사디아졸 유도체
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
AU2001286930A1 (en) 2000-08-30 2002-03-13 The Board Of Trustees Of The Leland Stanford Junior University Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
CA2450073C (fr) 2001-07-25 2017-08-29 Biomarin Pharmaceutical Inc. Compositions et procedes de modulation du transport a travers la barriere hematho-encephalique
AU2002359365B2 (en) 2001-11-09 2008-07-10 Gilead Sciences, Inc. A2B adenosine receptor antagonists
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
JP4995423B2 (ja) 2002-12-03 2012-08-08 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート 物質を血液−脳関門を渡って輸送するための人工低密度リポタンパク質キャリア
WO2005025511A2 (fr) 2003-09-10 2005-03-24 Cedars-Sinai Medical Center Administration assistee par les canaux potassiques d'agents a travers la barriere hemato-encephalique
BRPI0810082A2 (pt) 2007-03-29 2014-10-21 Novartis Ag 3-imidazolil-indóis para o tratamento de doenças proliferativas
WO2009002933A1 (fr) 2007-06-22 2008-12-31 Hydra Biosciences, Inc. Procédés et compositions pour le traitement de troubles
WO2010036821A1 (fr) 2008-09-24 2010-04-01 Hydra Biosciences, Inc. Méthodes et compositions pour le traitement de troubles respiratoires
ES2456515T3 (es) 2009-03-23 2014-04-22 Glenmark Pharmaceuticals S.A. Derivados de pirimidindiona fusionados como moduladores de TRPA1
WO2010125469A1 (fr) 2009-04-29 2010-11-04 Glenmark Pharmaceuticals, S.A. Composés hétérocycliques fusionnés à une pyrimidine dione en tant que modulateurs de trpa1
WO2011114184A1 (fr) 2010-03-15 2011-09-22 Glenmark Pharmaceuticals S.A. Amides de composés hétérocycliques à titre d'inhibiteurs de trpa1
WO2011132017A1 (fr) 2010-04-19 2011-10-27 Glenmark Pharmaceuticals S.A. Dérivés de pyrido[3,4-d]pyrimidinyl acétamide comme modulateurs de trpa1
KR101591153B1 (ko) 2010-12-20 2016-02-02 그렌마크 파머수티칼스 에스. 아. Trpa1 길항제로서의 2-아미노-4-아릴티아졸 화합물
EP2805718B1 (fr) 2012-01-17 2018-04-04 EA Pharma Co., Ltd. Dérivé d'amine hétérocyclique et produit pharmaceutique le contenant
HUE039931T2 (hu) 2013-02-20 2019-02-28 Lg Chemical Ltd Szfingozin-1-foszfát receptor agonisták, azok elkészítési eljárásai, és azokat aktív ágensként tartalmazó gyógyszerészeti készítmények
WO2015155306A1 (fr) 2014-04-11 2015-10-15 Almirall, S.A. Nouveaux antagonistes de trpa1
CA2975196A1 (fr) 2015-02-15 2016-08-18 F. Hoffmann-La Roche Ag Derives de 1-(het)arylsulfonyle- (pyrrolidine ou piperidine)-2-carboxamide et leur utilisation comme antagonistes de trpa1
WO2017060488A1 (fr) 2015-10-09 2017-04-13 Almirall, S.A. Nouveaux antagonistes de trpa1
US10138227B2 (en) * 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
JP7171567B2 (ja) 2016-11-28 2022-11-15 エフ．ホフマン－ラ ロシュ アーゲー 一過性受容体電位型チャネル阻害剤としてのオキサジアゾロン類
JP7178357B2 (ja) 2017-03-07 2022-11-25 エフ．ホフマン－ラ ロシュ アーゲー オキサジアゾール一過性受容器電位チャネル阻害剤
US10710994B2 (en) * 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors

Also Published As

Publication number Publication date
US10710994B2 (en) 2020-07-14
SG11202009136RA (en) 2020-10-29
IL304835A (en) 2023-09-01
AU2019237992B2 (en) 2025-01-30
TW202003510A (zh) 2020-01-16
PE20210660A1 (es) 2021-03-31
CN111867585A (zh) 2020-10-30
CR20200413A (es) 2020-11-23
JP7095106B2 (ja) 2022-07-04
CA3091486A1 (fr) 2019-09-26
CL2020002399A1 (es) 2020-12-18
TW202438496A (zh) 2024-10-01
UA128787C2 (uk) 2024-10-23
IL276654B2 (en) 2024-01-01
RU2020133430A (ru) 2022-04-19
PH12020551501A1 (en) 2021-09-06
KR102533094B1 (ko) 2023-05-16
EP3768260A1 (fr) 2021-01-27
IL276654B1 (en) 2023-09-01
US20200308161A1 (en) 2020-10-01
MX2020009657A (es) 2020-10-08
KR20230070333A (ko) 2023-05-22
TWI829676B (zh) 2024-01-21
ES3052569T3 (en) 2026-01-12
AU2019237992A1 (en) 2020-09-03
EP3768260B1 (fr) 2025-10-08
CO2020011852A2 (es) 2020-10-20
BR112020018983A2 (pt) 2020-12-29
JP2022126779A (ja) 2022-08-30
US11655245B2 (en) 2023-05-23
KR20200133358A (ko) 2020-11-27
JP2021518388A (ja) 2021-08-02
IL276654A (en) 2020-09-30
US20230121700A1 (en) 2023-04-20
WO2019182925A1 (fr) 2019-09-26
US20250122184A1 (en) 2025-04-17
EP3768260C0 (fr) 2025-10-08
US20190284179A1 (en) 2019-09-19
MY209839A (en) 2025-08-07
US12202824B2 (en) 2025-01-21

Similar Documents

Publication Publication Date Title
CL2020002399A1 (es) Inhibidores de canal de potencial de receptor transitorio de oxadiazol
DK3764956T3 (da) Fremgangsmåder til styring af resterende slitagetid for en stomianordning og tilhørende tilbehørsanordning
EP3830728A4 (fr) Remédiation d'attaques de recharge de vidage
CL2022000027A1 (es) Compuestos antagonistas de pcsk9. (divisional de solicitud 202003257).
DK4045039T3 (da) Hæmning af human integrin-alfa4beta7
EP4079000C0 (fr) Auto-localisation d'un dispositif audio
EP3843704A4 (fr) Formulations d'émulsion d'inhibiteurs de multikinase
DK3720442T3 (da) Inhibering af mutant idh-1
EP3892015A4 (fr) Rétroaction de sous-ensemble de base pour l'amélioration d'informations d'état de canal
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
EP3875542A4 (fr) Composition d'émulsion de silicone
EP3791927A4 (fr) Procédé de réglage d'éclairage et terminal
EP3870181A4 (fr) Formes cristallines d'un inhibiteur d'alk2
MA53648A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase
IL281769A (en) Cd40l antagonist and uses thereof
EP3928587A4 (fr) Configuration d'occasion de canal d'accès aléatoire
EP3747433A4 (fr) Association d'immunothérapie cellulaire
EP3994938A4 (fr) Acquisition d'informations d'état de canal
EP3735756A4 (fr) Indication de décalage de fréquence de porteuse non d'ancrage
IL286708A (en) Inhibitors of the n-terminal domain of the androgen receptor
EP3870179A4 (fr) Inhibition d'usp7
MA53010A (fr) Formulations d'un inhibiteur de axl/mer
EP3762456A4 (fr) Composition de dispersant d'asphaltène
EP3695265A4 (fr) Amplificateur de tension destiné à une lentille d'électromouillage
EP3963995A4 (fr) Sélection de priorité d'accès à un canal